Safety and efficacy of orally administered full-spectrum medicinal cannabis plant extract 0.08% THC (NTI-164) in children with autism spectrum disorder: An open-label study

Dima El-Sukkari, Kanan Sharma, Bobbi Fleiss, Dion L. Braganza, Alison Crichton, Michael C. Fahey
doi: https://doi.org/10.1101/2023.12.05.23299505

Article Information

doi 
https://doi.org/10.1101/2023.12.05.23299505
History 
  • December 9, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Author Information

  1. Dima El-Sukkari1,
  2. Kanan Sharma1,
  3. Bobbi Fleiss2,
  4. Dion L. Braganza1,
  5. Alison Crichton3,4 and
  6. Michael C. Fahey1,*
  1. 1Monash Children’s Hospital, Clayton, Victoria, Australia
  2. 2RMIT University, STEM College, Bundoora, Victoria, Australia
  3. 3Department of Paediatrics, Monash University,
  4. 4Developmental Paediatrics, Department of Paediatrics, Monash Children’s Hospital
  1. ↵*Corresponding author
    E-mail: Michael.Fahey{at}monash.edu
Back to top
Posted December 09, 2023.
Download PDF
Data/Code
Email
Safety and efficacy of orally administered full-spectrum medicinal cannabis plant extract 0.08% THC (NTI-164) in children with autism spectrum disorder: An open-label study
Dima El-Sukkari, Kanan Sharma, Bobbi Fleiss, Dion L. Braganza, Alison Crichton, Michael C. Fahey
medRxiv 2023.12.05.23299505; doi: https://doi.org/10.1101/2023.12.05.23299505
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area